期刊文献+

血浆B型利钠肽水平对非ST段抬高性急性冠脉综合征患者预后的预测价值 被引量:1

Relation of plasma brain natriuretic peptide levels on admission to prognosis in patients with non-ST segment elevation acute coronary syndrome
下载PDF
导出
摘要 目的评估血浆B型利钠肽(BNP)水平对非ST段抬高性急性冠脉综合征(NSTE-ACS)患者预后的预测价值。方法入选NSTE-ACS患者180例,所有患者于发病第24小时采用免疫荧光法测定血浆BNP水平,根据24 hBNP水平将患者分为血浆BNP≥80 ng/L组与BNP<80 ng/L组。对所有患者随访6个月,观察早期BNP水平与随访6个月主要不良心血管事件发生的关系。结果随访6个月,180例患者中有42例(23%)患者发生主要不良心血管事件,血浆BNP≥80 ng/L组患者主要不良心血管事件发生率明显高于BNP<80 ng/L组患者(P=0.003),在校正了年龄、性别、高血压病、糖尿病、高脂血症、吸烟及左室射血分数等影响预后的危险因素后,NSTE-ACS患者入院早期血浆BNP水平≥80 ng/L与随访6个月发生主要不良心血管事件显著相关[校正RR=3.625,95%CI(1.505~8.731),P=0.004]。结论 NSTE-ACS患者早期BNP水平增高有助于评价NSTE-ACS患者6个月主要不良心血管事件的发生,可应用于危险分层的评估。 Objective To investigate the relation between brain natriuretic peptide(BNP) levels on the first 24 hours after the onset of non-ST segment elevation acute coronary syndrome and the major adverse cardiovascular events(MACEs-ACS) 6 months later.MethodsConsecutive 180 patients with non-ST segment elevation acute coronary syndrome were studied,BNP plasma concentration levels were measured by fluorescence immunoassay at 24 hour from onset,patients were divided into two groups according to plasma BNP level,group A: BNP≥80 ng/L;group B:BNP80 ng/L.All patients were followed for 6 months.ResultsForty two patients suffered from MACEs at 6 months.the incidences of MACEs were more higher in group A than in group B(P=0.003),after adjusting for age,sex,hypertension,diabetes mellitus,smoking status,left ventricular ejection fraction,the elevated BNP levels(≥80 ng/L) were significantly associated with subsequent MACEs(adjusted relative risk [RR=3.625,95%CI(1.505~8.731),P=0.004].ConclusionElevated BNP levels(≥80 ng/L) on admission in patients with NSTE-ACS may be helpful assessing MACEs at 6 months later,may help guide risk stratification in patients with NSTE-ACS.
出处 《新疆医科大学学报》 CAS 2011年第8期864-867,共4页 Journal of Xinjiang Medical University
关键词 非ST段抬高性急性冠脉综合征 B型利钠肽 预后 plasma brain natriuretic peptide non-ST segment elevation acute coronary syndrome prognosis
  • 相关文献

参考文献10

  • 1Donald SC,Colin FLA,Michelle PK,et al.Serial bedside B-type natriuretic peptide strongly predicts prognosis in acute coronary syndrome independent of echocardiographic abnormalities[J].Am Heart J,2009,158:133-140.
  • 2焦媛,李宪伦,王勇,杨鹏,刘晓飞,张虎,彭文华,郑金刚,曾玉杰,柯元南.B型脑钠肽在评估非ST段抬高急性冠脉综合征患者预后中的价值[J].中国循环杂志,2009,24(5):333-336. 被引量:5
  • 3Morrow DA,de Lemos JA,Sabatine MS,et al.Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction:B-type natriuretic peptide and prognosis in TACTICS-TIMI 18 trial[J].J Am Coll Cardiol,2003,41:1264-1272.
  • 4David A,James AM,de Michael A.et al.Prognostic value of serial B-type natriuretic peptide testing during follow-up of patients with unstable coronary artery disease[J].JAMA,2005,294(22):2866-2871.
  • 5Hasdai D,Behar S,Wallentin L,et al.A prospective survey of the characteristics,treatments and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin;the Euro Heart Survey of Acute Coronary Syndromes[J].Eur Heart J,2002,23:1190-1201.
  • 6Sabatine MS,Morrow DA,James A,et al.Acute changes in circulating natriuretic peptide levels in relation to myocardial ischemia[J].J Am Coll Cardiol,2004,44:1988-1995.
  • 7Heeschen C,Hamm CW,Mitrovic V,et al.N-terminal pro-B-type natriuretic peptide levels for dynamic risk stratification of patients with acute coronary syndromes[J].Circulation,2004,110:3206-3212.
  • 8Morrow DA,Scirica BM,Sabatine MS,et al.B-type natriuretic peptide and the effect of ranolazine in patients with non-ST-segment elevation acute coronary syndromes.observations from the MERLIN-TIMI 36 (metabolic efficiency with ranolazine for less ischemia in non-ST elevation acute coronary-thrombolysis in myocardial infarction 36) trial[J].J Am Coll Cardiol,2010,55:1189-1196.
  • 9Sabatine MS,Morrow DA,de Lemos JA,et al.Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes:simultaneous assessment of troponin I,C-reactive protein,and B-type natriuretic peptide[J].Circulation,2002,105:1760-1763.
  • 10Jernberg T,Stridsberg M,Venge P,et al.N-terminal pro-brain natriuretic peptide on admission for early risk stratification of patients with chest pain and no ST-segment elevation[J].J Am Coll Cardiol,2002,40:437-445.

二级参考文献7

  • 1Ndrepepa G, Braun S, Mehilli J, et al. N-terminal pro-brain natriuretic peptide on admission in patients with acute myocardial infarction and correlation with scintigraphic infarct size, efficacy of reperfusion, and prognosis. Am J Cardiol, 2006,97 : 1151-1156.
  • 2Hirayama A, Kusuoka H, Yamamoto H, et al. Usefulness of plasma brain natriuretic Peptide concentration for predicting subsequent left ventricular remodeling after coronary angioplasty in patients with acute myocardial infarction. Am J Cardio1,2006,98:453-457.
  • 3Richards AM, Nicholls MG, Espiner EA, et al. B-type natriuretic pep- tides and ejection fraction for prognosis after myocardial infarction. Circulation, 2003,107 : 2786-2792.
  • 4Sabatine MS,Morrow DA,de Lemos JA,et al. Acute changes in circulating natriuretic peptide levels in relation to myocardial ischemia. J Am Coll Cardiol,2004,44 : 1988-1995.
  • 5Bassan R,Potsch A, Maisel A, et al. B-type natriuretic peptide: a novel early blood marker of acute myocardial infarction in patients with chest pain and no ST-segment elevation. Eur Heart J, 2005,26 : 234- 240.
  • 6de Lemos JA, Marrow DA, Bentley J H, et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med,2001,345:1014-1021.
  • 7Morrow DA, de Lemos J A, Sabatine MS, et al. Evaluation of B-type natriuretic peptide for risk assessment in unstable angia/non-ST-elevation myocardial infarction B-type natriuretic peptide and prognosis in TACTICS-TIMI 18. J Am Coil Cardiol,2003,41:1264-1272.

共引文献4

同被引文献10

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部